Lutronic: Aesthetic Aesthetic Menu Close
See All Press Releases

Lutronic Introduced New Cutting-Edge and Clinically Proven Technologies at 12th AMWC 2014

Lutronic, a leading innovator of aesthetic and medical technology, secured its global presence as a leading provider of laser, light-based, radiofrequency (RF) technologies at the 12th Annual Anti-Aging Medicine World Congress in Monte-Carlo, Monaco from April 3-5, 2014.

Dr. Glen Calderhead PhD DrMedSci, a founding member of the International Association for Laser and Sports Medicine (IASLM) and the World Medical Antiageing Association (WAMA), was invited by the AMWC organizing committee to deliver two special guest lectures during the congress scientific sessions for the European LED Academy on low level light therapy both as standalone and adjunctive treatments, represented by the HEALITE™ phototherapy system. Dr. Calderhead also gave a contributing lecture in the aesthetic dermatology session on the extended features of the SPECTRA™ XT, a new paradigm in Q-switched Nd:YAG laser treatment.

Dr. Jean-Luc H. Vigneron, M.D, a teacher at the Aesthetic Dermatology University of Paris V featured non ablative fractional resurfacing technology with the INFINI™, during a scientific session, in which microneedling RF treatment for skin resurfacing was highlighted.

On the evening of the first day of the congress, Lutronic hosted an exclusive symposium at the Fairmont Monte Carlo where nearly 80 clinicians participated to enhance their knowledge and expand their practice. During the symposium, Dr. Bettina Rümmelein, a senior aesthetic physician at the University Hospital, Zurich, shared her clinical experiences with the long-pulsed alexandrite and Nd:YAG combined platform, CLARITY™. “It is in constant use because it covers a wide range of indications and enables fast visible results, including effective, fast hair removal. Patients are very satisfied and so am I.” she stated. She was also willing to share her clinical experience of SPECTRA™ in treating pigmented lesions such as melasma, tattoo and any other dermal/epidermal pigmentation. “Patients can see significant improvements which I couldn’t achieve with the ruby Laser, and I have been using a new Nd:YAG-based multiplatform with extended functionality, the SPECTRA™ XT, for a couple of months and can see good results with 660 nm RuVY (Ruby-like Versatile YAG) Touch treatment for off-face pigmentation” she added.    

Dr. Matteo Tretti Clementoni, a plastic surgeon in Italy, a world-renowned physician, shared his knowledge of the INFINI™ for treating skin laxity, acne scars and neck lifting. He particularly emphasized how much value INFINI™ can bring to the treatment of facial contouring, sagging neck and skin laxity. “The secret of the device is that I can precisely deliver the exact amount of energy to achieve a controlled coagulation zone in the target area in the dermis, while protecting the skin surface” said Dr. Clementoni. “If you want to obtain clinical results with a short downtime and at low cost, INFINI™ is definitely a good choice” he said.

While on the subject of INFINI™, it also attracted a great deal of attention at the Lutronic booth during the AMWC from European clinicians who are not familiar with microneedling RF. As a result, many now INFINI™ represents a new trend for aesthetic procedures in Europe.

About Lutronic

Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 17 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, skin resurfacing, body/facial contouring, chronic pain and more.

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 240 intellectual properties including current and pending patents worldwide. With more than 250 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, and is ever expanding.